@article{38f38c315fc44f42bde8f66bf34c4e47,
title = "Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial",
author = "{EMPEROR-Reduced trial committees and investigators} and Subodh Verma and Dhingra, {Nitish K.} and Javed Butler and Anker, {Stefan D.} and Ferreira, {Joao Pedro} and Filippatos, {Gerasimos S.} and Januzzi, {James L.} and Lam, {Carolyn S.P.} and Naveed Sattar and Barbara Peil and Matias Nordaby and Martina Brueckmann and Pocock, {Stuart J.} and Faiez Zannad and Milton Packer and M. Packer and J. Butler and S. Pocock and F. Zannad and Ferreira, {J. P.} and M. Brueckmann and J. George and W. Jamal and Welty, {F. K.} and M. Palmer and T. Clayton and Parhofer, {K. G.} and Pedersen, {T. R.} and B. Greenberg and Konstam, {M. A.} and Lees, {K. R.} and P. Carson and W. Doehner and A. Miller and M. Haas and S. Pehrson and M. Komajda and I. Anand and J. Teerlink and A. Rabinstein and T. Steiner and H. Kamel and G. Tsivgoulis and J. Lewis and J. Freston and N. Kaplowitz and J. Mann and J. Petrie and S. Perrone and S. Baum",
note = "Funding Information: Graphical assistance, supported financially by Boehringer Ingelheim, was provided by Sally Neath and Charlie Bellinger of Elevate Scientific Solutions . Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",
year = "2022",
month = jan,
doi = "10.1016/S2213-8587(21)00292-8",
language = "English",
volume = "10",
pages = "35--45",
journal = "The Lancet Diabetes and Endocrinology",
issn = "2213-8587",
publisher = "Elsevier BV",
number = "1",
}
